This document is a guidance for industry issued by the Health Sciences Authority of Singapore, which provides regulatory requirements and GMP requirements for secondary packaging of therapeutic and medicinal products, including requirements for manufacturer's licence, application for manufacturer's licence and GMP certificate, obligations and responsibilities of licensed secondary packagers.
This document serves as an industry guidance issued by the Health Sciences Authority (HSA) regarding the secondary packaging of therapeutic and medicinal products. It details the regulatory requirements for manufacturers, including the necessity of holding a Manufacturer's Licence and complying with Good Manufacturing Practice (GMP) standards as per the PIC/S Guide.
The guidance covers specific operational aspects such as the interpretation of GMP principles for secondary packagers, requirements for personnel, premises, equipment, and documentation. It also addresses questions related to manufacturer licensing, batch release procedures, and the responsibilities of licensed secondary packagers in ensuring product quality and compliance with the Health Products Act and Medicines Act.
If the repackaging is carried out at a manufacturing site approved in the Product Registration, no notification or approval is required by the HSA. However, if performed at an unregistered site, consultation with the relevant branch is expected.
Release of a batch of finished product for supply is considered a manufacturing step and should be performed or overseen by a suitably qualified person appointed by the senior management of the organization, termed as 'Authorised Person'.
Yes, contract secondary packagers are required to keep reference and retention samples as part of their GMP compliance.